AgomAb Therapeutics (NASDAQ:AGMB) Trading 5.4% Higher – Here’s What Happened

AgomAb Therapeutics NV (NASDAQ:AGMB)’s share price shot up 5.4% on Wednesday . The company traded as high as $10.67 and last traded at $10.33. 97,030 shares changed hands during mid-day trading, a decline of 33% from the average session volume of 145,593 shares. The stock had previously closed at $9.80.

Analysts Set New Price Targets

A number of research firms have weighed in on AGMB. JPMorgan Chase & Co. began coverage on shares of AgomAb Therapeutics in a research note on Tuesday, March 3rd. They issued an “overweight” rating and a $32.00 price objective on the stock. Zacks Research raised shares of AgomAb Therapeutics to a “hold” rating in a research note on Wednesday, March 4th. Leerink Partners started coverage on shares of AgomAb Therapeutics in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $36.00 target price for the company. Wall Street Zen upgraded shares of AgomAb Therapeutics to a “hold” rating in a report on Tuesday, February 17th. Finally, Morgan Stanley started coverage on shares of AgomAb Therapeutics in a report on Tuesday, March 3rd. They issued an “overweight” rating and a $28.00 target price for the company. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, AgomAb Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $32.00.

AgomAb Therapeutics Trading Up 5.4%

The business has a fifty day moving average price of $11.04.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.